Tonix Pharmaceuticals Holding Corp. Stock
Our community identified positive and negative aspects for Tonix Pharmaceuticals Holding Corp. stock for the coming years. 2 users see the criterium "Worthwhile Investment for the next years" as a plus for the Tonix Pharmaceuticals Holding Corp. stock. On the other hand our users think that "EBIT growth" could be a problem in the future.
Pros and Cons of Tonix Pharmaceuticals Holding Corp. in the next few years
Pros
?
M***** P*******
?
W********* I********* f** t** n*** y****
?
S********** s********
Cons
?
G***** c******* t* c**********
?
C******** o* t** e**********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Tonix Pharmaceuticals Holding Corp. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Tonix Pharmaceuticals Holding Corp. | - | - | - | - | - | - | - |
| Heron Therapeutics Inc. | -0.770% | 1.801% | -17.320% | -57.946% | -36.580% | -71.740% | -95.128% |
| Evolus Inc | 0.560% | 4.046% | -22.078% | -56.098% | -33.945% | -51.351% | -67.857% |
| Sangamo Therapeutics Inc. | -1.650% | -15.717% | -37.386% | -65.319% | -36.993% | -83.471% | -97.618% |
Comments
Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) had its "buy" rating re-affirmed by analysts at Alliance Global Partners.
Show more
Ratings data for TNXP provided by MarketBeat
Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) had its "outperform" rating re-affirmed by analysts at Noble Financial. They now have a $70.00 price target on the stock.
Show more
Ratings data for TNXP provided by MarketBeat
Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Show more
Ratings data for TNXP provided by MarketBeat
